The biology of Epstein-Barr virus: Lessons learned from the virus and the host

Current Opinion in Immunology

Volumn 11, Issue 4, 1999, Pages 365-370

  Cohen, Jeffrey I ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

ANTIGEN RECOGNITION; ANTIGENIC VARIATION; APOPTOSIS; B LYMPHOCYTE ACTIVATION; CYTOTOXIC T LYMPHOCYTE; EPSTEIN BARR VIRUS; HUMAN; IMMUNOTHERAPY; INFECTIOUS MONONUCLEOSIS; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; REVIEW; VIRUS CARCINOGENESIS; VIRUS CELL INTERACTION; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS LATENCY;

EID: 0033178519     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(99)80062-4     Document Type: Article

References (51)

1. Steven N, Annels NE, Kumar A, Leese AM, Kurilla MG, Rickinson AB: Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med 1997, 185:1605-1617.
2. + cells that the host devotes to controlling EBV infection
3. Tan LC, Gudgeon N, Annels NE, Hansasuta P, O'Callaghan CA, Rowland-Jones S, McMichael AJ, Rickinson AB, Callan MFC: A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. J Immunol 1999, 162:1827-1835. See annotation [2••].
4. + T cells in acute infectious mononucleosis. Nat Med 1996, 2:906-911.
5. Silins S, Cross SM, Krauer KG, Moss DJ, Schmidt CW, Misko IS: A functional link of major TCR expansions in healthy adults caused by persistent Epstein-Barr virus infection. J Clin Invest 1998, 102:1551-1558.
6. Sayos J, Wu C, Morra N, Wang N, Zhang X, Allen D, van Schaik S, Notarangelo L, Geha R, Roncarolo MG et al.: The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998, 395:462-469. This paper, along with [7•,8•], identifies the genetic defect in XLPD, there-by identifying a new signaling pathway critical for controlling EBV infection.
7. Coffey AJ, Brooksbank PA, Brandau O, Oohashi T, Howell GR, Bye JM, Cahn AP, Durham J, Heath P, Wray P et al.: Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 1998, 20:129-135. See annotation [6••].
8. Nichols KE, Harkin DP, Levitz S, Krainer M, Kolquist KA, Genovese C, Bernard A, Ferguson M, Zuo L, Snyder E et al.: Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci USA 1998, 95:13765-13770. See annotation [6bull;•].
9. Faulkner GC, Burrows SR, Khanna R, Moss DJ, Bird AG, Crawford DH: X-linked agammaglobulinemia patients are not infected with Epstein-Barr virus: Implications for the biology of the virus. J Virol 1998; 73:1555-1564.
10. Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C, Kieff E: The Epstein-Barr virus transforming protein LMP1 engages signalling proteins for the tumor necrosis factor receptor family. Cell 1995, 80:389-399.
11. Devergne O, Hatzivassiliou E, Izumi KM, Kaye MF, Kleijnen E, Kieff E, Mosialos G: Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: Role in NF-KB activation. Mol Cell Biol 1996, 16:7098-7108.
12. Izumi KM, Kieff ED: The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-KB. Proc Natl Acad Sci USA 1997, 94:12592-12597.
13. Miller WE, Cheshire JL, Raab-Traub N: Interaction of tumor necrosis factor receptor-associated factor signaling proteins with the latent membrane protein 1 PXQXT motif is essential for induction of epidermal growth factor receptor expression. Mol Cell Biol 1998, 18:2835-2844.
14. Devergne O, McFarland EC, Mosialos G, Izumi KM, Ware CF, Kieff E: Role of the TRAF binding site and NF-KB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol 1998, 72:7900-7908.
15. Kilger E, Kieser A, Baumann M, Hammerschmidt W: Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which stimulates an activated CD40 receptor. EMBO J 1998, 17:1700-1709.
16. Busch LK, Bishop GA: The EBV transforming protein, latent membrane protein 1, mimics and cooperates with CD40 signaling in B lymphocytes. J Immunol 1999, 162:2555-2561. This paper shows that the carboxyl terminus of LMP-1 is sufficient for B cell signaling and immunoglobulin secretion.
17. Hatzivassiliou E, Miller WE, Raab-Traub N, Kieff E, Mosialos G: A fusion of the EBV Latent Membrane Protein-1 (LMP-1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor, nuclear factor-KB, and stress-activated protein kinase. J Immunol 1998, 60:1116-1121.
18. Eliopoulos AG, Blake SMS, Floettmann JE, Rowe M, Young LS: Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J Virol 1999, 73:1023-1035.
19. Liebowitz D: Epstein-Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med 1998, 338:1413-1421. This paper shows that LMP-1 signaling pathways are important for EBV-associated human tumors in vivo.
20. Cohen JI: Epstein-Barr virus and the immune system: Hide and seek. JAMA 1997, 278:510-513.
21. Caldwell RG, Wilson JB, Anderson SJ, Longnecker R: Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998, 9:405-411. This paper shows that expression of LMP-2 alone can allow B cells that do not produce immunoglobulin to localize in lymphoid organs.
22. Babcock GJ, Decker LL, Volk M, Thorley-Lawson DA: EBV persistence in memory B cells in vivo. Immunity 1998, 9:395-404. This paper defines the cell in which EBV is latent in vivo.
23. Khan G, Miyashita EM, Yang B, Babcock GJ, Thorley-Lawson D: Is EBV persistence in vivo a model for B cell homeostasis? Immunity 1996, 5:173-179.
24. Fanidi A, Hancock DC, Littlewodd TD: Suppression of c-myc induced apoptosis by the Epstein-Barr virus gene product BHRF1. J Virol 1998, 72:8392-8395.
25. Foghsgaard L, Jaattela M: The ability of BHRF1 to inhibit apoptosis is dependent on stimulus and cell type. J Virol 1997, 71:7509-7517.
26. Dawson CW, Dawson J, Jones R, Ward K, Young LS: Functional differences between BHRF1, the Epstein-Barr virus-encoded bcl-2 homologue, and bcl-2 in human epithelial cells. J Virol 1998, 72:9016-9024.
27. Wang S, Rowe M, Lundgren E: Expression of the Epstein-Barr virus transforming protein LMP1 causes a rapid and transient stimulation of the bcl-2 homologue Mcl-1 levels in B-cell lines. Cancer Res 1997, 56:4610-4613.
28. Fries KL, Miller WE, Raab-Traub N: Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. J Virol 1996, 70:8653-8659.
29. Kawanishi M: Expression of Epstein-Barr virus latent membrane protein 1 protects Jurkat T cells from apoptosis induced by serum deprivation. Virology 1997, 228:244-250.
30. Kulwichit W, Edwards RH, Davenport EM, Baskar JF, Godfrey V, Raab-Traub N: Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc Natl Acad Sci USA 1998, 95:11963-11968. This paper shows that expression of LMP-1 alone can induce B cell tumors.
31. Komano J, Sugiura M, Takadfa K: Epstein-Barr virus contributes to the malignant potential and to apoptosis resistance in Burkitt's lymphoma cell line Akata. J Virol 1998, 72:9150-9156.
32. Ruf IK, Rhyne PW, Yang H, Borza CM, Hutt-Fletcher LM, Cleveland JL, Sample JT: Epstein-Barr virus regulates c-MYC, apoptosis, and tumorigenicity in Burkitt lymphoma. Mol Cell Biol 1999, 19:1651-1660. This paper shows that oncogenicity of EBV correlates with resistance to apoptosis.
33. Kanegane H, Wakiguchi H, Kanegane C, Kurashige T, Tosato G: Viral interleukin-10 in chronic active Epstein-Barr virus infection. J Infect Dis 1997, 176:254-257.
34. Takayama T, Nishioka Y, Lu L, Lotze MT, Tahara H, Thomson AW: Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation 1998, 66:1567-1574.
35. Liu Y, Malefy R, Briere F, Parham C, Bridon J-M, Banchereau J, Moore KW, Xu J: The EBV IL-10 homologue is a selective agonist with impaired binding to the IL-10 receptor. J Immunol 1997, 158:604-613.
36. Strockbine LD, Cohen JI, Farrah T, Lynman SD, Wagener F, DuBoise RF, Armitage RJ, Spriggs MK: The Epstein-Barr virus BARF1 gene encodes a novel soluble CSF-1 receptor. J Virol 1998, 72:4015-4021.
37. Devergne O, Birkenbach M, Kieff E: Epstein-Barr virus-induced gene 3 and the p35 subunit of interleukin 12 form a novel heterodimeric hematopoietin. Proc Natl Acad Sci USA 1997, 94:12041-12046.
38. Khanna R, Burrows SR, Thomson SA, Moss DJ, Cresswell P, Poulsen LM, Cooper L: Class I-processing-defective Burkitt's lymphoma cells are recognized by CD4+ EBV-specific CTLs. J Immunol 1997, 158:3619-3625.
39. Levitskaya J, Shapiro A, Leonchiks A, Ciechanover A, Masucci MG: Inhibition of ubiquitin/proteosome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA 1997, 94:12616-12621.
40. Shapiro A, Imreh M, Leonchiks A, Imreh S, Masucci MG: Minimal glycine-alanine repeat prevents the interaction of ubiquinated IKB-alpha with the proteosome: A new mechanism for selective inhibition of proteolysis. Nat Med 1998, 4:939-944.
41. Mukherjee S, Trivedi P, Dorfman DM, Klein G, Townsend A: Murine cytotoxic T lymphocytes recognize an epitope in an EBNA-1 fragment, but fail to lyse EBNA-1-expressing mouse cells. J Exp Med 1998, 187:445-450.
42. Blake N, Lee S, Redchenko I, Thomas W, Steven N, Leese A, Steigerwald-Mullen P, Kurilla M, Frappier L, Rickinson A: Human CD8+ T cell responses to EBV EBNA-1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. Immunity 1997, 7:791-802.
43. Khanna R, Slade RW, Poulsen L, Moss DJ, Burrows SR, Nicholls J, Burrows JM: Evolutionary dynamics of genetic variation in Epstein-Barr virus isolates of diverse geographic origins: Evidence for immune pressure-independent genetic drift. J Virol 1997, 71:8340-8346.
44. Khanna R, Sherritt M, Burrows SR: EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: Potential use of gp350/gp85 CTL epitopes for vaccine design. J Immunol 1999, 162:3063-3069.
45. O'Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L: Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev 1997, 157:195-216.
46. Rooney CM, Smith CA, Ng YC, Loftin SK, Sixbey JW, Gan Y, Srivastava D-K, Bowman LC, Krance RA, Brenner MK, Heslop HE: Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphomas in allogeneic transplant recipients. Blood 1998, 5:1549-1555. This paper shows that EBV-specific CTLs can be effective for treating EBV-associated lymphoproliferative disease.
47. Sing AP, Ambinder RF, Hong DJ, Jensen M, Batten W, Petersdorf E, Greenberg PD: Isolation of Epstein-Barr Virus (EBV)-specific cytotoxic T lymphocytes that lyse Reed-Sternberg cells: Implications for immune-mediated therapy of EBV+ Hodgkin's disease. Blood 1997, 89:1978-1986.
48. Roskrow MA, Suzuki N, Gan Y-J, Sixbey JW, Ng CYC, Kimbrough S, Hudson M, Brenner MK, Heslop HE, Rooney CM: Epstein-Barr Virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 1998, 91:2925-2934. This paper demonstrates the potential for treating Hodgkin's disease with EBV-specific CTLs.
49. Chodosh J, Holder VP, Gan Y-J, Belaumi A, Sample J, Sixbey JW: Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype. J Infect Dis 1998, 177:1194-1201.
50. Sgardari C, Farber JM, Angiolillo AL, Fang L, Teruya-Feldstein J, Burd PR, Yao L, Gupta G, Kanegane C, Tosato G: Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo. Blood 1997, 89:2635-2643.
51. Kenney JL, Guinness ME, Curiel T, Lacy J: Antisense to the Epstein-Barr Virus (EBV)-encoded Latent Membrane Protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells. Blood 1998, 92:1721-1727.